is discontinued ( 7 , 8 ). The American and European guidelines recommend maintaining ATD for approximately 12–18 months, and the remission rates achieved are 50–55% ( 1 , 9 ). However, some studies, including a randomized clinical trial, report
Meihua Jin, Ahreum Jang, Chae A Kim, Tae Young Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, and Won Gu Kim
Yiyun Cui, Jinlong Chen, Rui Guo, Ruize Yang, Dandan Chen, Wei Gu, Francis Manyori Bigambo, and Xu Wang
have shown that the long-term remission rate of GD children after ATD therapy is about 17–33% ( 3 , 4 ), which is lower than that of adults, and they are more likely to relapse after ATD withdrawal. Relapse after ATD therapy may lead to prolonged
Sun Mi Park, Yoon Young Cho, Ji Young Joung, Seo Young Sohn, Sun Wook Kim, and Jae Hoon Chung
influenced by intrathyroid iodide content, and that chronic exposure to excessive iodine resulted in a decrease in ATD uptake in thyrocytes. Other studies have reported that the remission rate is parallel to the estimates of declining iodine intake, and a
J Karmisholt, S L Andersen, I Bulow-Pedersen, A Krejbjerg, B Nygaard, and A Carlé
Introduction Graves’ hyperthyroidism (GH) is an autoimmune disease mainly affecting the thyroid gland ( 1 , 2 ). The disease is usually transient with remission occurring within a period of 1–2 years after treatment with anti-thyroid drugs
Pei-Wen Wang, I-Ya Chen, Suh-Hang Hank Juo, Edward Hsi, Rue-Tsuan Liu, and Ching-Jung Hsieh
spontaneous remission. However, hyperthyroidism recurred in 30–60% of GD patients who discontinued the antithyroid medication [ 1 , 2 , 3 , 4 , 5 ]. Understanding of predictors of relapse of disease might help clinicians better individualize their patient
Mohamed E. Ahmed, Mohamed A. Mahgoub, Mohamed G. Alnedar, Seif I. Mahadi, Maha Alzubeir, Lamyaa A.M. El Hassan, ElWaleed M. Elamin, and Ahmed Mohammed El Hassan
months the patient was still in remission from T-cell-rich thymoma and the associated myasthenia gravis. Discussion The cervical swelling with retrosternal extension is a fairly common presentation of goiter. However, the pressure symptoms such as
Shakeel Kautbally, Orsalia Alexopoulou, Chantal Daumerie, François Jamar, Michel Mourad, and Dominique Maiter
the development of a goiter and hyperthyroidism. Treatment should aim at inducing a rapid and permanent remission of hyperthyroidism and a disappearance of TSI with minimal morbidity. Thyroid surgery and radioiodine (RAI) therapy are both used as
Laure Felix, Peggy Jacon, Maxime Lugosi, Justine Cristante, Julie Roux, and Olivier Chabre
radiologic density on the subsequent CT scans, until remission of thyrotoxicosis. This provided the first analysis of the evolution of intrathyroid iodine accumulation throughout the time course of AIT, showing a close association between thyroid radiologic
Matthieu Bosset, Maxime Bonjour, Solène Castellnou, Zakia Hafdi-Nejjari, Claire Bournaud-Salinas, Myriam Decaussin-Petrucci, Jean Christophe Lifante, Agnès Perrin, Jean-Louis Peix, Philippe Moulin, Geneviève Sassolas, Michel Pugeat, and Françoise Borson-Chazot
micro-PTC. This second group included only patients with locoregional recurrence (lymph nodes or/and operated thyroid bed) or metastasis. Secondary outcome was the final status of patients: remission, persistent disease, or undetermined status. Patients
Akira Miyauchi, Takumi Kudo, Mitsuyoshi Hirokawa, Yasuhiro Ito, Minoru Kihara, Takuya Higashiyama, Tomonori Yabuta, Hiroo Masuoka, Hisakazu Shindo, Kaoru Kobayashi, and Akihiro Miya
other patients in this category had no structural diseases postoperatively. The patients who had 4 or more undetectable Tg measurements only were regarded as being in ‘biochemical remission'. In the patients who had 1-3 detectable Tg values and
